EcoDrugPlus

Kit Proto-Oncogene Receptor Tyrosine Kinase

Ensembl ID : ENSXETG00000021049
Gene Symbol: KIT
11 Enzyme and pathways 5 View Cross-references
134 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Kirsten Rat Sarcoma Viral Oncogene Homolog Like

Ensembl ID : ENSXETG00000043145
Gene Symbol: KRASL
71 Enzyme and pathways 5 View Cross-references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSXETG00000005650
Gene Symbol: LYN
42 Enzyme and pathways 5 View Cross-references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Malt1 Paracaspase

Ensembl ID : ENSXETG00000021146
Gene Symbol: MALT1
8 Enzyme and pathways 5 View Cross-references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mapk Activated Protein Kinase 2

Ensembl ID : ENSXETG00000023673
Gene Symbol: MAPKAPK2
5 View Cross-references
235 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mapk Interacting Serine/threonine Kinase 2

Ensembl ID : ENSXETG00000013667
Gene Symbol: MKNK2
5 View Cross-references
224 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mcl1, Bcl2 Family Apoptosis Regulator

Ensembl ID : ENSXETG00000008910
Gene Symbol: MCL1
5 View Cross-references
240 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mdm2 Proto-Oncogene

Ensembl ID : ENSXETG00000001434
Gene Symbol: MDM2
24 Enzyme and pathways 5 View Cross-references
282 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSXETG00000021752
Gene Symbol: MET
28 Enzyme and pathways 5 View Cross-references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mpl Proto-Oncogene, Thrombopoietin Receptor

Ensembl ID : ENSXETG00000037903
Gene Symbol: MPL
5 View Cross-references
186 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSXETG00000016102
Gene Symbol: MLST8
24 Enzyme and pathways 5 View Cross-references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

N-Acetylated Alpha-Linked Acidic Dipeptidase 2

Ensembl ID : ENSXETG00000011728
Gene Symbol: FOLH1
3 Enzyme and pathways 5 View Cross-references
210 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).